The University of Rochester is a health and research institute ideally suited to help achieve the goals of the Southwest Oncology Group (SWOG). These goals include: improve standards of care to adult cancer patients advance the understanding of cancer biology via translational research, promote treatment and supportive care to outreach sites through NCI-supported clinical trial participation, explore innovative multi-modality treatment combinations, support cancer prevention efforts, and refine methodology of clinical cancer trials. Our activity (2002 -to date) as fiinded members of the Southwest Oncology Group, indicates our continuous investment in and commitment to clinical and basic laboratory research, patient care, and education. To date we have enrolled 762 cases and served as study chair or co-chair of 14 SWOG protocols;27 multidisciplinary members actively participated in one or more committees (seven faculty members served as chair and/or co-chair of 21 committees). Eleven faculty members coordinated or co-coordinated 20 protocols and 2studies currently in development. As we recruit more clinical-scientific faculty and further develop interactive, collaborative, multimodality cancer programs, we plan to produce additional important contributions to SWOG. The University of Rochester SWOG program involves 1) The University's James P. Wilmot Cancer Center and the University's Strong Memorial Hospital, a primary tertiary care center. The Cancer Center and hospital serves a population of approximately 1.4 million people 2) Six outreach facilities located In the regronal Northeast section of the country (contiguous states of New York and Massachusetts) Through this Southwest Oncology Group apphcation, our program continues to support and attain objectives to 1) participatein multi-modal Phase II/III clinical trials, 2) accelerate the advances of cancer therapy in adult patients through increased recruitment, 3) enhance basic science clinical interactions;4) support cancer control and prevention initiatives, 5) provide wide dissemination of information through quality and timely data collection and publications, 6) continueservice to the administrative agenda of the Southwest Oncology Group.

Public Health Relevance

The aim of our cooperative group participation is to advance our understanding of malignant diseases and to improve our ability to treat people. These cooperative group studies answer important therapeutic questions via large clinical trials that aim to improve prevention, treatment, and cure of adult cancers. New approaches are being developed that allow more rapid wide spread applications of therapy for adult cancers

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011083-46
Application #
8410098
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2013-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
46
Fiscal Year
2013
Total Cost
$377,652
Indirect Cost
$133,217
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10
Cook, James R; Goldman, Bryan; Tubbs, Raymond R et al. (2014) Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. Am J Surg Pathol 38:494-501
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Gustafson, Heather L; Yao, Song; Goldman, Bryan H et al. (2014) Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol 89:639-45
Friedberg, Jonathan W; Unger, Joseph M; Burack, W Richard et al. (2014) R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. Br J Haematol 166:382-9
Ellis, Georgiana K; Barlow, William E; Gralow, Julie R et al. (2011) Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-21
Gold, Philip J; Goldman, Bryan; Iqbal, Syma et al. (2010) Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 5:1472-6
Slovak, Marilyn L; Bedell, Victoria; Lew, Danika et al. (2010) Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 119:391-8
Litzow, Mark R; Othus, Megan; Cripe, Larry D et al. (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148:217-25
Clark, Joseph I; Moon, James; Hutchins, Laura F et al. (2010) Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 116:424-31

Showing the most recent 10 out of 146 publications